0001654954-22-008910.txt : 20220628 0001654954-22-008910.hdr.sgml : 20220628 20220628163206 ACCESSION NUMBER: 0001654954-22-008910 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220624 FILED AS OF DATE: 20220628 DATE AS OF CHANGE: 20220628 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WILLS STEPHEN T CENTRAL INDEX KEY: 0001103883 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15543 FILM NUMBER: 221050563 MAIL ADDRESS: STREET 1: PALATIN TECHNOLOGIES, INC. STREET 2: 4B CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PALATIN TECHNOLOGIES INC CENTRAL INDEX KEY: 0000911216 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 954078884 STATE OF INCORPORATION: NJ FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 4B CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: 609-495-2200 MAIL ADDRESS: STREET 1: 4B CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 FORMER COMPANY: FORMER CONFORMED NAME: INTERFILM INC DATE OF NAME CHANGE: 19930825 4 1 section16.xml PRIMARY DOCUMENT X0306 4 2022-06-24 0000911216 PALATIN TECHNOLOGIES INC PTN 0001103883 WILLS STEPHEN T PALATIN TECHNOLOGIES, INC. 4B CEDAR BROOK DRIVE CRANBURY NJ 08512 false true false false Executive VP and CFO/COO Common Stock 2022-06-24 4 A false 40659 0 A 9360658 D Stock Option (Right to Buy) 0.55 2022-06-24 4 A false 497000 0 A 2025-06-22 2031-06-22 Common Stock 497000 497000 D Stock Option (Right to Buy) 0.55 2022-06-24 4 A false 186375 0 A 2025-06-22 2031-06-22 Common Stock 186375 186375 D Restricted share units granted under the 2011 Stock Incentive Plan (the "Plan"), each of which represents the right to receive, without further payment, one share of common stock. On June 22, 2021, the Company granted performance-based restricted stock units to its executive officers which were contingent upon an increase in common stock available for issuance under the Plan, which increase was approved by our stockholders on June 24, 2022. The Compensation Committee certified on June 22, 2022, contingent upon approval of an increase in common stock available under the Plan, that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. Stock options granted under the Plan, each of which represents the right to receive, upon payment of the exercise price, one share of common stock. On June 22, 2021, the Company granted time-based options to its executive officers which vest at the rate of 25% per year, starting in June 2022, contingent upon an increase in common stock available for issuance under the Plan, which increase was approved by our stockholders on June 24, 2022 Stock options granted under the Plan, each of which represents the right to receive, upon payment of the exercise price, one share of common stock. On June 22, 2021, the Company granted performance-based options to its executive officers which were contingent upon an increase in common stock available for issuance under the Plan, which increase was approved by our stockholders on June 24, 2022. The Compensation Committee certified on June 22, 2022, contingent upon approval of an increase in common stock available under the Plan, that a defined performance objective as to 75% of the target number of stock option shares for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. /s/ Stephen T. Wills by Stephen A. Slusher, Attorney-in-Fact 2022-06-28